Disease of respiratory system
Conditions
Interventions
Esketamine group:The induction dose of esketamine 0.5 mg/kg + propofol 2-3 mg/kg + rocuronium 0.3 mg/kg
the maintenance dose of esketamine 0.5-3 mg/(kg.h) + propofol 4-9 mg/(kg.h).
Remifentanil group:The induction dose of remifentanil was 1 µg/kg, combined with 2-3 mg/kg of propofol and 0.3 mg/kg of rocuronium
the maintenance dose was 3-9 µg/(kg.h) of remifentanil and 4-9 mg/(kg.h) of propofol.
Sponsors
Affiliated Hospital of Guizhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. American Society of Anesthesiologists (ASA) classification levels I, II, and III; 2. 18 kg/m^2 < BMI < 30 kg/m^2; 3. Age 18 - 75 years old (including the boundary value), gender not restricted; 4. Patients scheduled for painless fiberoptic bronchoscopy; 5. Patients voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with contraindications to general anesthesia, or who have experienced anesthesia accidents in the past; 2. Those with a history of hyperthyroidism; 3. Those with mental disorders (such as schizophrenia, mania, mental confusion, etc.) or cognitive dysfunction; 4. Those who have been taking benzodiazepine sedatives for a long time (continuously or intermittently), or those who have used opioid analgesics before the randomization or within 7 days of using anesthetic drugs; 5. Those with severe anemia or abnormal coagulation function; 6. Pregnant or lactating women; 7. Those with severely difficult airways (modified Mallory score of level IV); 8. Those who have a history of drug abuse or alcohol abuse within the past 2 years; 9. Those who are allergic to or have contraindications to the drugs used in this study; 10. Those who have participated in other clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence rate of bronchospasm; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic data;Bronchial dilation effect indicators;Respiratory and hemodynamic indicators;The incidence rate of various adverse events during the perioperative period;Anesthesia effect evaluation indicators; | — |
Countries
China
Contacts
Public ContactJiang Ke
Affiliated Hospital of Guizhou Medical University
Outcome results
None listed